Biotech Values

[keitern]

Thanks, Dew, for highlighting that aspect again. The Atryn choice has been difficult from a stock appreciation point of view because of the first couple steps in the pathway not being particularly lucrative. It makes perfect sense, however, if we are able to end up with an approved DIC drug as an "endaround" and Atryn still available for other treatments in addition to HD and DIC. I think I am correct in thinking there are still more applications for Atryn.